Vanina Popova

1.4k total citations · 1 hit paper
22 papers, 727 citations indexed

About

Vanina Popova is a scholar working on Pharmacology, Experimental and Cognitive Psychology and Biological Psychiatry. According to data from OpenAlex, Vanina Popova has authored 22 papers receiving a total of 727 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pharmacology, 12 papers in Experimental and Cognitive Psychology and 7 papers in Biological Psychiatry. Recurrent topics in Vanina Popova's work include Treatment of Major Depression (20 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (8 papers) and Tryptophan and brain disorders (7 papers). Vanina Popova is often cited by papers focused on Treatment of Major Depression (20 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (8 papers) and Tryptophan and brain disorders (7 papers). Vanina Popova collaborates with scholars based in United States, Belgium and Spain. Vanina Popova's co-authors include Wayne C. Drevets, Rosanne Lane, Jaskaran Singh, Kimberly Cooper, Ella Daly, Pilar Lim, Madhukar H. Trivedi, Patricio Molero, Michael E. Thase and David Hough and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Neuropsychopharmacology.

In The Last Decade

Vanina Popova

20 papers receiving 718 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

2019 483 citations Vanina Popova, Ella Daly et al. American Journal of Psychiatry profile →

Peers

Countries citing papers authored by Vanina Popova

Since Specialization

Citations

This map shows the geographic impact of Vanina Popova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanina Popova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanina Popova more than expected).

Fields of papers citing papers by Vanina Popova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanina Popova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanina Popova. The network helps show where Vanina Popova may publish in the future.

Co-authorship network of co-authors of Vanina Popova

This figure shows the co-authorship network connecting the top 25 collaborators of Vanina Popova. A scholar is included among the top collaborators of Vanina Popova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanina Popova. Vanina Popova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Esketamine Monotherapy in Adults With Treatment-Resistant Depression 2025 ·JAMA Psychiatry ·Adam Janik, Xin Qiu, Rosanne Lane, Vanina Popova, Wayne C. Drevets, Carla M. Canuso, Matthew Macaluso, Gregory W. Mattingly, Richard C. Shelton, John Zajecka, Dong‐Jing Fu	4
2	Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study 2025 ·The International Journal of Neuropsychopharmacology ·(unknown), Li Chen, Rosanne Lane, (unknown), Wayne C. Drevets, Randall L. Morrison, Gerard Sanacora, Samuel T. Wilkinson, (unknown), Acioly L.T. Lacerda, Jong‐Woo Paik, Vanina Popova, Dong‐Jing Fu	3
3	Efficacy and safety of esketamine nasal spray as monotherapy in adults with treatment-resistant depression: a randomized, double-blind, placebo-controlled study 2024 ·Neuroscience Applied ·Adam Janik, Xi Qiu, (unknown), Vanina Popova, (unknown), Carla M. Canuso, Dong‐Jing Fu	1
4	Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study 2024 ·Neuropsychopharmacology ·Mark E. Schmidt, Iva Kezic, Vanina Popova, Rama Melkote, Peter van der Ark, Darrel J. Pemberton, Guy Mareels, Carla M. Canuso, Maurizio Fava, Wayne C. Drevets	21
5	A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics 2023 ·Neuropsychiatric Disease and Treatment ·Lien Wang, Xiaowei Chen, (unknown), Heidi De Smedt, Vanina Popova, Dong‐Jing Fu, Carla M. Canuso, Wayne C. Drevets, (unknown)	0
6	Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant 2023 ·Health and Quality of Life Outcomes ·Carol Jamieson, Vanina Popova, Ella Daly, Kimberly Cooper, Wayne C. Drevets, Heather Rozjabek, Jaskaran Singh	7
7	Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study 2023 ·Neuropsychopharmacology ·(unknown), Li Chen, Rosanne Lane, (unknown), Wayne C. Drevets, Randall L. Morrison, Gerard Sanacora, Samuel T. Wilkinson, Vanina Popova, Dong‐Jing Fu	69
8	Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression 2022 ·Neuropsychiatric Disease and Treatment ·Joachim Morrens, Maju Mathews, Vanina Popova, (unknown), Benoît Rive, (unknown), Carol Jamieson, Qiaoyi Zhang	12
9	Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant 2022 ·CNS Drugs ·Lysbeth Floden, Stacie Hudgens, Carol Jamieson, Vanina Popova, Wayne C. Drevets, Kimberly Cooper, Jaskaran Singh	8
10	Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials 2021 ·Neuropsychiatric Disease and Treatment ·(unknown), (unknown), Ibrahim Turkoz, Vanina Popova, W. Vaughn McCall, Maju Mathews, Frank Wiegand	7
11	Efficacy and safety of treatment with ampasse: the results of a randomized, double-blind, placebo-controlled trial in patients with chronic cerebrovascular disorders 2021 ·S S Korsakov Journal of Neurology and Psychiatry ·А. А. Скоромец, С. В. Котов, (unknown), Vanina Popova, (unknown), (unknown)	6
12	Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies 2021 ·CNS Drugs ·Richard L. Doty, Vanina Popova, (unknown), Maggie Fedgchin, Ella Daly, Adam Janik, Rachel Ochs-Ross, Rosanne Lane, Pilar Lim, (unknown), Rama Melkote, Carol Jamieson, Jaskaran Singh, Wayne C. Drevets	14
13	Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant 2020 ·Journal of Affective Disorders ·Stacie Hudgens, Lysbeth Floden, (unknown), Carol Jamieson, Vanina Popova, Maggie Fedgchin, Wayne C. Drevets, Kimberly Cooper, Rosanne Lane, Jaskaran Singh	45
14	PND1 USE OF CLINICAL GLOBAL IMPRESSIONS-SEVERITY (CGI-S) TO ASSESS RESPONSE TO ANTIDEPRESSANT TREATMENT IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION 2020 ·Value in Health ·Joachim Morrens, Maju Mathews, Vanina Popova, (unknown), (unknown), (unknown), Carol Jamieson, (unknown)	0
15	Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials 2020 ·The International Journal of Neuropsychopharmacology ·Ziad S. Saad, Derrek P. Hibar, Maggie Fedgchin, Vanina Popova, Maura L. Furey, Jaskaran Singh, Hartmuth C. Kolb, Wayne C. Drevets, Guang Chen	20
16	175 Determining Meaningful Change in Depression Symptoms Assessed with PHQ-9 and SDS in Treatment-resistant Depression Trials of Esketamine Nasal Spray 2020 ·CNS Spectrums ·Stacie Hudgens, Lysbeth Floden, (unknown), Carol Jamieson, Vanina Popova, Maggie Fedgchin, Wayne C. Drevets, Kimberly Cooper, Rosanne Lane, Jaskaran Singh	1
17	Effect of esketamine nasal spray on cognition in patients with treatment-resistant depression: results from five phase-3 studies 2019 ·European Neuropsychopharmacology ·Robert M. Morrison, Jaskaran Singh, Ella Daly, Maggie Fedgchin, Ewa Wajs, (unknown), Rachel Ochs-Ross, Vanina Popova, (unknown), (unknown), Pilar Lim, Kay M. Cooper, Paul Maruff, David Hough, (unknown), Husseini K. Manji	1
18	Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study breakdown → 2019 ·American Journal of Psychiatry ·Vanina Popova, Ella Daly, Madhukar H. Trivedi, Kimberly Cooper, Rosanne Lane, Pilar Lim, Christine Mazzucco, David Hough, Michael E. Thase, Richard C. Shelton, Patricio Molero, Eduard Vieta, Malek Bajbouj, Husseini K. Manji, Wayne C. Drevets, Jaskaran Singh	483
19	Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression 2019 ·European Neuropsychopharmacology ·Vanina Popova, Ella Daly, Madhukar H. Trivedi, Kevin Cooper, (unknown), Pilar Lim, Christine Mazzucco, David Hough, Michael E. Thase, Richard C. Shelton, Patricio Molero, Eduard Vieta, Malek Bajbouj, Husseini K. Manji, Wayne C. Drevets, Jaskaran Singh	1
20	S111. Randomized, Double-Blind Study of Flexibly-Dosed Intranasal Esketamine Plus Oral Antidepressant Vs. Active Control in Treatment-Resistant Depression 2018 ·Biological Psychiatry ·Vanina Popova, Ella Daly, Madhukar H. Trivedi, Kimberly Cooper, (unknown), Pilar Lim, Christine Mazzucco, David Hough, Michael E. Thase, Richard C. Shelton, Patricio Molero, Eduard Vieta, Malek Bajbouj, Husseini K. Manji, Wayne C. Drevets, Jaskaran Singh	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact